Premium
Introduction: Perampanel—New mode of action and new option for patients with epilepsy
Author(s) -
Steinhoff Bernhard J.
Publication year - 2014
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.12495
Subject(s) - perampanel , epilepsy , antagonist , ampa receptor , medicine , pharmacology , neuroscience , anesthesia , psychology , psychiatry , receptor , glutamate receptor
Summary With perampanel the first‐in‐class selective alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolprepionic acid (AMPA) receptor antagonist has been finally approved for add‐on treatment in patients with focal‐onset seizures. This suggests additional therapeutic potential in hitherto difficult‐to‐treat epilepsies.